POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Immune Biosolutions begins Phase I clinical trial stages for its inhaled immunotherapy treatment

Christian Fernsby |
Québec based Immune Biosolutions announces the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.

Article continues below




The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source.

This treatments aims to be complementary to vaccination and could be added to the tools used by health professionals, particularly to fight the virus of patients infected with COVID-19 and those at high risk of complications.

The inhalation treatment developed by Immune Biosolutions allows antibodies to pass through the respiratory tract and directly access the lungs to act as a viral extinguisher. The simplicity of the inhalation delivery method adds to the attributes of this innovation.

To develop this treatment, the Sherbrooke-based biotechnology company identified antibodies from two human patients infected with COVID-19. The two patients ultimately recovered from the virus.

The Phase I clinical trial, which is being conducted in South Africa, is a randomized, double blind, placebo controlled, single site study designed to evaluate the safety, tolerability and preliminary efficacy of IBIO123 in symptomatic COVID-19 patients. Recruitment of volunteers is ongoing.

The primary objective is to define the effects of IBIO123 in terms of its safety and tolerability compared to a placebo. The secondary objectives are to determine the effects of IBIO123 on the viral load and clearance of SARS-CoV-2 virus as well as on the general clinical status of participants and on symptom improvement, again compared to the placebo.

This discovery is the result of a close collaboration between several private and public Canadian organizations which stemmed from over more than a year. In the spring of 2021, Immune Biosolutions was awarded $13.4 million in funding from the Government of Canada's Strategic Innovation Fund (SIF) to develop and validate its promising immunotherapy treatment.

"We believe that IBIO123 is a potentially ideal candidate to treat symptomatic patients in the acute phase and possibly prevent long-term complications from the infection. We are excited to eventually allow the population as a whole to benefit from it," said Luc Paquet, Chief Corporate Development Officer of Immune Biosolutions.


What to read next

Cancer 'vaccine' eliminates tumors in mice with amazing, bodywide effects
Cancer exports molecular 'saboteurs' to remotely disarm immune system
Biopsies during early treatment predict response to melanoma immunotherapy